Sagimet Biosciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SGMT research report →
Companysagimet.com
Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne.
- CEO
- David A. Happel
- IPO
- 2023
- Employees
- 14
- HQ
- San Mateo, CA, US
Price Chart
Valuation
- Market Cap
- $218.11M
- P/E
- -5.01
- P/S
- 0.00
- P/B
- 2.13
- EV/EBITDA
- -3.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.57%
- ROIC
- -47.55%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-51,038,000 · -12.01%
- EPS
- $-1.58 · -8.97%
- Op Income
- $-56,889,000
- FCF YoY
- -7.58%
Performance & Tape
- 52W High
- $11.41
- 52W Low
- $3.15
- 50D MA
- $6.18
- 200D MA
- $6.67
- Beta
- 3.63
- Avg Volume
- 1.42M
Get TickerSpark's AI analysis on SGMT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 20, 26 | Grauer Andreas | other | 264,759 |
| Apr 20, 26 | Grauer Andreas | other | 0 |
| Feb 19, 26 | Rozek Elizabeth | other | 44,000 |
| Feb 19, 26 | Rozek Elizabeth | other | 88,000 |
| Feb 19, 26 | Martins Eduardo Bruno | other | 44,000 |
| Feb 19, 26 | Martins Eduardo Bruno | other | 88,000 |
| Feb 19, 26 | Happel David | other | 128,000 |
| Feb 19, 26 | Happel David | other | 256,000 |
| Feb 19, 26 | Chauche Thierry | other | 88,000 |
| Feb 19, 26 | Chauche Thierry | other | 44,000 |
Our SGMT Coverage
We haven't published any research on SGMT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SGMT Report →